3Kirstl AR,Stanford JL,et al.Vitamin and mineral supplenment use is associated with reduced risk of prostate cancer[J].Cancer Epidemil Biomarkers Prev, 1999,8(10):887-892.
2Barrass B JR, Thurairaja R, Persad RA.More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer. BJU Int,2004,93:1175 -1176.
3Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy:recommendations for diagnosis and therapies. Cancer,2004,100: 892-899.
4Higano CS. Understanding treatments for bone and bone metastases in patients with prostate cancer: a practical review and guide for the cli- nician. Urol Clin North Am,2004,31:331-352.
5Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol,2003,21:392-398.
6Roodman GD. Mechanism of bone metastasis. N Engl J Med, 2004,15:1655-1664.
7Gilbert SM, Olsson CA, Benson MC, et al. The role of intravenous zoledronic acid in the treatment of high-risk prostate cancer. Cur Opin Urol,2003 ,13 :133-135.
8Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res,2002,62:6538-6544.
9Koupparis A, Ramsden A, Persad C. Cognitive effects of hormonal treatment for prostate cancer. BJU Int,2004,93:915-916.
